Header Logo

Connection

WILLIAM WONG to Hepatitis C, Chronic

Back to Details
This is a "connection" page, showing publications WILLIAM WONG has written about Hepatitis C, Chronic.
WILLIAM WONG
Connection Strength
5.967
Hepatitis C, Chronic
  1. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology. 2024 08 01; 80(2):440-450.
    View in: PubMed
    Score: 0.635
  2. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver Int. 2024 Jun; 44(6):1383-1395.
    View in: PubMed
    Score: 0.634
  3. Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings. Liver Int. 2023 04; 43(4):805-818.
    View in: PubMed
    Score: 0.588
  4. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in?a Publicly Funded Health System. Value Health. 2022 02; 25(2):247-256.
    View in: PubMed
    Score: 0.535
  5. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open. 2021 Jan-Mar; 9(1):E167-E174.
    View in: PubMed
    Score: 0.515
  6. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
    View in: PubMed
    Score: 0.504
  7. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat. 2020 12; 27(12):1419-1429.
    View in: PubMed
    Score: 0.498
  8. A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value Health. 2020 01; 23(1):127-137.
    View in: PubMed
    Score: 0.471
  9. A model-based framework for chronic hepatitis C prevalence estimation. PLoS One. 2019; 14(11):e0225366.
    View in: PubMed
    Score: 0.471
  10. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015 Feb 17; 187(3):E110-E121.
    View in: PubMed
    Score: 0.336
  11. Engagement with the HCV care cascade among high-risk groups: A population-based study. Hepatol Commun. 2023 09 01; 7(9).
    View in: PubMed
    Score: 0.152
  12. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023 04 11; 195(14):E499-E512.
    View in: PubMed
    Score: 0.149
  13. Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. CMAJ Open. 2021 Jul-Sep; 9(3):E897-E906.
    View in: PubMed
    Score: 0.134
  14. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open. 2019 11 11; 9(11):e027491.
    View in: PubMed
    Score: 0.117
  15. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int. 2020 01; 40(1):51-59.
    View in: PubMed
    Score: 0.116
  16. Cost Effectiveness of Hepatocellular Carcinoma Surveillance?After a Sustained Virologic Response to Therapy?in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1840-1849.e16.
    View in: PubMed
    Score: 0.110
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.